Human Equilibrative Nucleoside Transporter 1 (hENT1) Levels Predict Response to Gemcitabine in Patients With Biliary Tract Cancer (BTC)

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|11|1|123-129

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.11, Iss.1, 2011-01, pp. : 123-129

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine

By Sasaki Takashi

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 708-713

Springer Publishing Company

Access to resources Recommend Favorite

Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer

By Tsavaris Nikolas Kosmas Christos Gouveris Panagiotis Gennatas Kostadinos Polyzos Aris Mouratidou Despina Tsipras Heracles Margaris Helias Papastratis George Tzima Evanthia Papadoniou Nikitas Karatzas Gavrilos Papalambros Efstathios

Investigational New Drugs, Vol. 22, Iss. 2, 2004-04 ,pp. : 193-198

Springer Publishing Company

Access to resources Recommend Favorite

Fine tuning of rabbit equilibrative nucleoside transporter activity by an alternatively spliced variant*

By Wu Sharon K. Ann David K. Kim Kwang-Jin Lee Vincent H. L.

Journal of Drug Targeting, Vol. 13, Iss. 8-9, 2005-09 ,pp. : 521-533

Informa Healthcare

Access to resources Recommend Favorite

Nucleoside transporter-mediated uptake and release of [ 3 H]l-adenosine in DDT 1 MF-2 smooth muscle cells

By Foga I.O. Geiger J.D. Parkinson F.E.

European Journal of Pharmacology, Vol. 318, Iss. 2, 1996-12 ,pp. : 455-460

Elsevier

Access to resources Recommend Favorite

Gemcitabine: A Critical Nucleoside for Cancer Therapy

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 1076-1087

Bentham Science Publishers

Access to resources Recommend Favorite